Oncopeptides AB (publ)

LSE:0RN4 Stock Report

Market Cap: SEK 319.3m

Oncopeptides Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of 0RN4?
Owner TypeNumber of SharesOwnership Percentage
Individual Insiders1,762,4700.819%
VC/PE Firms27,296,25512.7%
Institutions37,543,09517.4%
General Public148,584,42669%

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 127.5%.

Top Shareholders

Top 22 shareholders own 31.76% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
12.7%
Odlander, Fredrikson & Co. AB
27,296,255SEK 40.5m0%3.42%
6.48%
Avanza Fonder AB
13,936,083SEK 20.7m0%0.03%
4.85%
Nordnet Pensionsförsäkring Ab, Asset Management Arm
10,438,896SEK 15.5m-0.46%0.29%
3.85%
Industrifonden
8,285,258SEK 12.3m0%1.59%
2.1%
Handelsbanken Asset Management
4,520,183SEK 6.7m0%no data
0.5%
SEB Investment Management AB
1,068,552SEK 1.6m0%no data
0.4%
Jakob Lindberg
868,331SEK 1.3m0%no data
0.24%
Storebrand Fonder AB,
526,824SEK 781.8k0%no data
0.23%
Per Wold-Olsen
497,616SEK 738.5k0%no data
0.16%
FCG Fonder AB
347,456SEK 515.6k0%0.01%
0.065%
Skandia Fonder AB
140,274SEK 208.2k0%no data
0.056%
Eva Nordström
120,200SEK 178.4k0%no data
0.047%
Jarl Jungnelius
101,042SEK 150.0k0%no data
0.046%
Klaas Bakker
100,000SEK 148.4k0%no data
0.026%
Cecilia Wennborg
55,092SEK 81.8k0%no data
0.0093%
Sofia Heigis
20,104SEK 29.8k0%no data
0.004%
Fund Development & Advisory AG
8,500SEK 12.6k0%no data
0.0036%
State Street Global Advisors, Inc.
7,791SEK 11.6k30%no data
0.002%
Danske Bank A/S, Asset Management Arm
4,326SEK 6.4k0%no data
0.0019%
Deutsche Asset & Wealth Management
4,000SEK 5.9k0%no data
0.0002%
Nordea Investment Management, AB
437SEK 638.70%no data
0.00004%
Sara Svardgren
85SEK 127.70%no data

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/24 00:17
End of Day Share Price 2024/12/23 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Oncopeptides AB (publ) is covered by 7 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Erik HultgårdCarnegie Investment Bank AB
Patrik LingDNB Markets
Robert BurnsH.C. Wainwright & Co.